234 related articles for article (PubMed ID: 22895066)
21. PLGA-CTAB curcumin nanoparticles: Fabrication, characterization and molecular basis of anticancer activity in triple negative breast cancer cell lines (MDA-MB-231 cells).
Meena R; Kumar S; Kumar R; Gaharwar US; Rajamani P
Biomed Pharmacother; 2017 Oct; 94():944-954. PubMed ID: 28810532
[TBL] [Abstract][Full Text] [Related]
22. A novel histone deacetylase inhibitor TMU-35435 enhances etoposide cytotoxicity through the proteasomal degradation of DNA-PKcs in triple-negative breast cancer.
Wu YH; Hong CW; Wang YC; Huang WJ; Yeh YL; Wang BJ; Wang YJ; Chiu HW
Cancer Lett; 2017 Aug; 400():79-88. PubMed ID: 28450160
[TBL] [Abstract][Full Text] [Related]
23. Liposomal co-delivery of curcumin and albumin/paclitaxel nanoparticle for enhanced synergistic antitumor efficacy.
Ruttala HB; Ko YT
Colloids Surf B Biointerfaces; 2015 Apr; 128():419-426. PubMed ID: 25797481
[TBL] [Abstract][Full Text] [Related]
24. Paclitaxel and curcumin coadministration in novel cationic PEGylated niosomal formulations exhibit enhanced synergistic antitumor efficacy.
Alemi A; Zavar Reza J; Haghiralsadat F; Zarei Jaliani H; Haghi Karamallah M; Hosseini SA; Haghi Karamallah S
J Nanobiotechnology; 2018 Mar; 16(1):28. PubMed ID: 29571289
[TBL] [Abstract][Full Text] [Related]
25. Down-regulation of topoisomerase II by camptothecin does not prevent additive activity of the topoisomerase II inhibitor etoposide in vitro.
Stahl M; Kasimir-Bauer S; Harstrick A
Anticancer Drugs; 1997 Aug; 8(7):671-6. PubMed ID: 9311443
[TBL] [Abstract][Full Text] [Related]
26. A role for PKCzeta in potentiation of the topoisomerase II activity and etoposide cytotoxicity by wortmannin.
Reis C; Giocanti N; Hennequin C; Mégnin-Chanet F; Fernet M; Filomenko R; Bettaieb A; Solary E; Favaudon V
Mol Cancer Ther; 2005 Oct; 4(10):1457-64. PubMed ID: 16227394
[TBL] [Abstract][Full Text] [Related]
27. The role of cell cycle regulation and apoptosis triggering in determining the sensitivity of leukemic cells to topoisomerase I and II inhibitors.
Dubrez L; Goldwasser F; Genne P; Pommier Y; Solary E
Leukemia; 1995 Jun; 9(6):1013-24. PubMed ID: 7596166
[TBL] [Abstract][Full Text] [Related]
28. PARP inhibitor Olaparib Enhances the Apoptotic Potentiality of Curcumin by Increasing the DNA Damage in Oral Cancer Cells through Inhibition of BER Cascade.
Molla S; Hembram KC; Chatterjee S; Nayak D; Sethy C; Pradhan R; Kundu CN
Pathol Oncol Res; 2020 Oct; 26(4):2091-2103. PubMed ID: 31768967
[TBL] [Abstract][Full Text] [Related]
29. Assessing dose-dependent differences in DNA-damage, p53 response and genotoxicity for quercetin and curcumin.
Sun B; Ross SM; Trask OJ; Carmichael PL; Dent M; White A; Andersen ME; Clewell RA
Toxicol In Vitro; 2013 Sep; 27(6):1877-87. PubMed ID: 23764886
[TBL] [Abstract][Full Text] [Related]
30. Interaction of celecoxib with different anti-cancer drugs is antagonistic in breast but not in other cancer cells.
El-Awady RA; Saleh EM; Ezz M; Elsayed AM
Toxicol Appl Pharmacol; 2011 Sep; 255(3):271-86. PubMed ID: 21763710
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of fibroblast growth factor receptor-signaling sensitizes imatinib-resistant gastrointestinal stromal tumors to low doses of topoisomerase II inhibitors.
Boichuk S; Dunaev P; Galembikova A; Mustafin I; Valeeva E
Anticancer Drugs; 2018 Jul; 29(6):549-559. PubMed ID: 29697413
[TBL] [Abstract][Full Text] [Related]
32. Comparison of the effect of three different topoisomerase II inhibitors combined with cisplatin in human glioblastoma cells sensitized with double strand break repair inhibitors.
Macieja A; Kopa P; Galita G; Pastwa E; Majsterek I; Poplawski T
Mol Biol Rep; 2019 Aug; 46(4):3625-3636. PubMed ID: 31020489
[TBL] [Abstract][Full Text] [Related]
33. Valproic acid induces p21 and topoisomerase-II (alpha/beta) expression and synergistically enhances etoposide cytotoxicity in human glioblastoma cell lines.
Das CM; Aguilera D; Vasquez H; Prasad P; Zhang M; Wolff JE; Gopalakrishnan V
J Neurooncol; 2007 Nov; 85(2):159-70. PubMed ID: 17534580
[TBL] [Abstract][Full Text] [Related]
34. Histone deacetylase inhibitor sodium butyrate suppresses DNA double strand break repair induced by etoposide more effectively in MCF-7 cells than in HEK293 cells.
Li L; Sun Y; Liu J; Wu X; Chen L; Ma L; Wu P
BMC Biochem; 2015 Jan; 16():2. PubMed ID: 25592494
[TBL] [Abstract][Full Text] [Related]
35. Tunicamycin induces resistance to camptothecin and etoposide in human hepatocellular carcinoma cells: role of cell-cycle arrest and GRP78.
Hsu JL; Chiang PC; Guh JH
Naunyn Schmiedebergs Arch Pharmacol; 2009 Nov; 380(5):373-82. PubMed ID: 19777212
[TBL] [Abstract][Full Text] [Related]
36. The role of the DNA mismatch repair system in the cytotoxicity of the topoisomerase inhibitors camptothecin and etoposide to human colorectal cancer cells.
Jacob S; Aguado M; Fallik D; Praz F
Cancer Res; 2001 Sep; 61(17):6555-62. PubMed ID: 11522654
[TBL] [Abstract][Full Text] [Related]
37. Apoptosis is the most efficient death-pathway in tumor cells after topoisomerase II inhibition.
El-Awady RA; Ali MM; Saleh EM; Ghaleb FM
Saudi Med J; 2008 Apr; 29(4):558-64. PubMed ID: 18382799
[TBL] [Abstract][Full Text] [Related]
38. Development of curcumin-loaded gemini surfactant nanoparticles: Synthesis, characterization and evaluation of anticancer activity against human breast cancer cell lines.
Karimpour M; Feizi MAH; Mahdavi M; Krammer B; Verwanger T; Najafi F; Babaei E
Phytomedicine; 2019 Apr; 57():183-190. PubMed ID: 30776589
[TBL] [Abstract][Full Text] [Related]
39. Diversity of DNA damage response of astrocytes and glioblastoma cell lines with various p53 status to treatment with etoposide and temozolomide.
Sato Y; Kurose A; Ogawa A; Ogasawara K; Traganos F; Darzynkiewicz Z; Sawai T
Cancer Biol Ther; 2009 Mar; 8(5):452-7. PubMed ID: 19305157
[TBL] [Abstract][Full Text] [Related]
40. Oxocrebanine: A Novel Dual Topoisomerase inhibitor, Suppressed the Proliferation of Breast Cancer Cells MCF-7 by Inducing DNA Damage and Mitotic Arrest.
Yu L; Han S; Lang L; Song H; Zhang C; Dong L; Jia S; Zhang Y; Xiao D; Liu J; Xu Y; Zhang X
Phytomedicine; 2021 Apr; 84():153504. PubMed ID: 33611211
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
